KA-3002
/ KYinno
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
March 06, 2024
The bispecific antibody KA-3002, targeting PSMA and 4-1BB, specifically enhances T cell activity within prostate tumors
(AACR 2024)
- "KA-3002 shows neither aggregation nor degradation. In conclusion, the BsAb KA-3002, developed with our nanobody antibody discovery platform, emerges as a promising pre-clinical candidate drug for the treatment of prostate cancer."
IO biomarker • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor
1 to 1
Of
1
Go to page
1